Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Indoco Remedies Limited (INDOCO.NS)
Mumbai, IN
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.48% | -4.99% | +9.20% | +7.94% | -17.54% | -5.78% | -11.95% | -37.57% | -37.21% | -16.18% | +320.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | +1 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.8% ★ Q1'26: +21.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-24.2% Q1'26: +45.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-4.6% Q1'26: +11.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.8% Q1'26: +3.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.8% Q1'26: +3.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.9% Q1'26: -1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×7.69× Q1'26: 5.48× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2009 actual |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 1 EPS Ana. |
Mar 2028 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.63B
est: 3.56B (-26.2%)
|
3.98B
est: 4.08B (-2.3%)
|
4.84B
est: 5.13B (-5.7%)
|
5.69B
est: 5.69B (-0.1%)
|
6.30B
est: 6.48B (-2.6%)
|
7.33B
est: 7.44B (-1.6%)
|
8.57B
est: 8.67B (-1.1%)
|
10.04B
est: 9.88B (+1.6%)
|
10.97B
est: 11.06B (-0.8%)
|
10.18B
est: 10.34B (-1.5%)
|
9.42B
est: 9.87B (-4.5%)
|
10.80B
est: 10.81B (-0.1%)
|
12.19B
est: 12.62B (-3.5%)
|
15.04B
est: 15.47B (-2.8%)
|
16.40B
est: 17.02B (-3.6%)
|
17.88B
est: 18.22B (-1.9%)
|
16.65B
est: 17.09B (-2.6%)
|
17.59B
16.37B – 20.36B
+2.9% YoY
|
20.86B
20.72B – 21.00B
+18.6% YoY
|
23.75B
22.34B – 24.63B
+13.9% YoY
|
| EBITDA |
672.24M
est: 562.95M (+19.4%)
|
582.21M
est: 400.00M (+45.6%)
|
724.79M
est: 678.65M (+6.8%)
|
852.54M
est: 809.07M (+5.4%)
|
943.65M
est: 630.98M (+49.6%)
|
1.13B
est: 593.36M (+89.9%)
|
1.63B
est: 1.02B (+60.7%)
|
1.72B
est: 1.68B (+2.4%)
|
1.69B
est: 1.67B (+1.3%)
|
1.34B
est: 1.46B (-7.9%)
|
822.44M
est: 892.82M (-7.9%)
|
1.20B
est: 504.22M (+138.3%)
|
2.27B
est: 855.90M (+165.5%)
|
3.25B
est: 992.43M (+227.1%)
|
2.88B
est: 1.09B (+165.0%)
|
2.67B
est: 2.48B (+7.4%)
|
1.06B
est: 2.33B (-54.6%)
|
2.40B
2.23B – 2.77B
+2.8% YoY
|
2.84B
2.82B – 2.86B
+18.6% YoY
|
3.24B
3.04B – 3.35B
+13.9% YoY
|
| EBIT |
652.23M
est: 367.76M (+77.4%)
|
460.33M
est: 448.38M (+2.7%)
|
589.87M
est: 520.29M (+13.4%)
|
660.05M
est: 566.40M (+16.5%)
|
699.40M
est: 742.66M (-5.8%)
|
817.94M
est: 800.04M (+2.2%)
|
1.16B
est: 1.06B (+9.7%)
|
1.08B
est: 1.35B (-19.4%)
|
1.05B
est: 1.23B (-15.1%)
|
652.39M
est: 895.75M (-27.2%)
|
106.50M
est: 626.06M (-83.0%)
|
521.98M
est: 60.04M (+769.3%)
|
1.54B
est: 616.06M (+150.1%)
|
2.47B
est: 714.33M (+246.4%)
|
2.17B
est: 782.80M (+176.6%)
|
1.75B
est: 1.45B (+20.4%)
|
-81.40M
est: 1.36B (-106.0%)
|
1.40B
1.30B – 1.62B
+2.8% YoY
|
1.66B
1.65B – 1.67B
+18.6% YoY
|
1.89B
1.78B – 1.96B
+13.9% YoY
|
| Net Income |
300.97M
est: 317.31M (-5.2%)
|
420.92M
est: 358.25M (+17.5%)
|
511.18M
est: 529.09M (-3.4%)
|
463.42M
est: 567.51M (-18.3%)
|
426.59M
est: 524.97M (-18.7%)
|
579.81M
est: 490.83M (+18.1%)
|
828.13M
est: 687.10M (+20.5%)
|
829.80M
est: 941.70M (-11.9%)
|
770.61M
est: 916.22M (-15.9%)
|
411.61M
est: 738.15M (-44.2%)
|
-29.04M
est: 382.42M (-107.6%)
|
241.17M
est: -32.98M (+831.3%)
|
930.46M
est: 282.23M (+229.7%)
|
1.55B
est: 327.25M (+373.0%)
|
1.42B
est: 358.62M (+296.7%)
|
984.60M
est: 657.70M (+49.7%)
|
-737.40M
est: -294.97M (-150.0%)
|
-951.50M
-1.02B – -586.38M
-222.6% YoY
|
567.43M
549.35M – 585.50M
+159.6% YoY
|
1.26B
889.72M – 1.31B
+121.6% YoY
|
| SGA |
—
est: 632.69M (-100.0%)
|
—
est: 1.32B (-100.0%)
|
—
est: 1.63B (-100.0%)
|
884.69M
est: 1.72B (-48.6%)
|
2.07B
est: 2.17B (-4.6%)
|
2.62B
est: 2.61B (+0.4%)
|
1.66B
est: 3.36B (-50.5%)
|
326.80M
est: 3.67B (-91.1%)
|
1.14B
est: 4.22B (-73.1%)
|
1.13B
est: 4.26B (-73.4%)
|
1.09B
est: 4.13B (-73.7%)
|
1.52B
est: 5.16B (-70.5%)
|
1.29B
est: 6.21B (-79.2%)
|
1.51B
est: 7.20B (-79.0%)
|
3.36B
est: 7.89B (-57.4%)
|
2.12B
est: 4.15B (-48.9%)
|
5.97B
est: 3.90B (+53.4%)
|
4.01B
3.73B – 4.64B
+2.8% YoY
|
4.75B
4.72B – 4.78B
+18.6% YoY
|
5.41B
5.09B – 5.61B
+13.9% YoY
|
| EPS |
3.41
est: 3.70 (-7.9%)
|
4.57
est: 4.62 (-1.1%)
|
5.55
est: 5.44 (+2.0%)
|
5.03
est: 5.30 (-5.0%)
|
4.64
est: 5.42 (-14.4%)
|
6.29
est: 5.71 (+10.2%)
|
8.99
est: 9.86 (-8.8%)
|
8.89
est: 10.45 (-15.0%)
|
8.36
est: 9.54 (-12.3%)
|
4.47
est: 7.28 (-38.6%)
|
-0.32
est: 0.72 (-144.4%)
|
2.62
est: 2.60 (+0.8%)
|
10.10
est: 11.78 (-14.2%)
|
16.80
est: 16.83 (-0.1%)
|
15.44
est: 18.25 (-15.4%)
|
10.68
est: 7.45 (+43.4%)
|
-8.61
est: -3.34 (-157.8%)
|
-8.18
-11.50 – -6.59
-144.8% YoY
|
6.38
6.17 – 6.58
+178.0% YoY
|
12.83
10.00 – 14.71
+101.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aditi Milind Panandikar | MD & Executive Director | 91M | female |
| Sundeep Vasant Bambolkar | Joint MD & Executive Director | 81M | male |
| Pramod Ghorpade | Chief Financial Officer | 19M | male |
| Ramanathan Hariharan | Head of Legal, Company Secretary & Compliance Officer | 6M | male |
| Suresh Govind Kare | Non-Executive Chairman & Whole time Director | 200.0K | male |
| Rajan Saawant | Vice President of Corporate HR | — | male |
| Rajesh Usgaonker | Chief Marketing Officer | — | male |
| Kavita Inamdar | Chief Technical Officer | — | — |
| Dileep Mahajan | Vice President of Operations | — | male |
| Ajay Karajagi | President of Sales & Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INDOCO.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
